Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1]
P.T. Francis.
Biochemical and pathological correlates of cognitive andbehavioural change in DLB/PDD.
J Neurol., 256 (2009), pp. S280-S285
[2]
K. Ueda, H. Fukushima, E. Masliah.
Molecular cloning of cDNA enconding an unrecognizable component of amyloid in Alzheimer's disease.
Proc Natl Acaad Sci USA., 90 (1993), pp. 11282-11286
[3]
M.H. Polymeropoulos, C. Lavedan, E. Leroy, S.E. Ide, A. Dehejia, A. Dutra, et al.
Mutation in the alpha-synuclin gene identified in families with Parkinson's disease.
Science., 276 (1997), pp. 2045-2047
[4]
K. Kosaka, M. Yoshimura, K. Ikeda, H. Budka.
Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree –a new disease?.
Clin Neuropathol., 3 (1984), pp. 185-192
[5]
H. Braak, K. Del Tredici, U. Rub, R.A. De Vos, E.N. Jansen Steur, E. Braak.
Staging of brain pathology related to sporadic Parkinson's disease.
Neurobiol Aging., 24 (2003), pp. 197-211
[6]
I.G. McKheit, D.W. Dickson, J. Lowe.
Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium.
Neurology., 65 (2005), pp. 1863-1872
[7]
L.S. Libow, P.G. Frisina, V. Haroutunian, D.P. Perl, D.P. Purohit.
Parkinson's disease dementia: a diminished role for the Lewy body.
Parkinsonism Relat Disord., 15 (2009), pp. 572-575
[8]
D.W. Dickson, H. Fujishiro, A. DelleDonne, J. Menke, Z. Ahmed, K.J. Klos, et al.
Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease.
Acta Neuropathol., 115 (2008), pp. 437-444
[9]
L. Parkkinen, T. Kauppinen, T. Pirttila, J.M. Autere, I. Alafuzoff.
Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia.
Ann Neurol., 57 (2005), pp. 82-91
[10]
W.R. Gibb, A.J. Lees.
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
J Neurol Neurosurg Psychiatry., 51 (1988), pp. 745-752
[11]
K.A. Jellinger.
Formation and development of Lewy pathology: a critical update.
J Neurol., 256 (2009), pp. S270-S279
[12]
W.J. Shulz-Schaeffer.
The synaptic pathology of alfa-synuclein aggregation in dementia with Lewy bodies.
Parkinson's desease and Parkinson's disease dementia. Acta Neuropathol., 120 (2010), pp. 131-143
[13]
I. Alafuzoff, P.G. Ince, T. Arzberger, S. Al-Sarraj, J. Bell, I. Bodi, et al.
Staging/typing of Lewy body related alfa-synuclein pathology: a study of the BrainNet Europe Consortium.
Acta Neuropathol., 117 (2009), pp. 635-652
[14]
T.G. Beach, C.H. Adler, L. Lue, L.I. Sue, J. Bachalakuri, J. Henry, et al.
Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction.
Acta Neuropathol., 117 (2009), pp. 613-634
Copyright © 2011. SEGG
